托奇利珠单抗治疗新冠肺炎肺炎的疗效

Journal of cellular immunology Pub Date : 2021-12-31 DOI:10.33696/immunology.3.119

Kathy Tin, A. Fernandes, Roderick A. Go

{"title":"托奇利珠单抗治疗新冠肺炎肺炎的疗效","authors":"Kathy Tin, A. Fernandes, Roderick A. Go","doi":"10.33696/immunology.3.119","DOIUrl":null,"url":null,"abstract":"The COVID-19 pandemic has now impacted the global population for over a year. It has been devastating for many and has challenged us all in many ways. While the advent of vaccinations looks to curtail the number of cases, multiple challenges to ending the pandemic remain, including the advent of variants, vaccine hesitancy, access to vaccines, and the impaired efficacy of vaccines in immunocompromised persons. Thus, it is still essential to continue investigating treatments for COVID-19.","PeriodicalId":73644,"journal":{"name":"Journal of cellular immunology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Return of Tocilizumab for Patients with COVID-19 Pneumonia\",\"authors\":\"Kathy Tin, A. Fernandes, Roderick A. Go\",\"doi\":\"10.33696/immunology.3.119\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The COVID-19 pandemic has now impacted the global population for over a year. It has been devastating for many and has challenged us all in many ways. While the advent of vaccinations looks to curtail the number of cases, multiple challenges to ending the pandemic remain, including the advent of variants, vaccine hesitancy, access to vaccines, and the impaired efficacy of vaccines in immunocompromised persons. Thus, it is still essential to continue investigating treatments for COVID-19.\",\"PeriodicalId\":73644,\"journal\":{\"name\":\"Journal of cellular immunology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cellular immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33696/immunology.3.119\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cellular immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33696/immunology.3.119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

2019冠状病毒病大流行对全球人口的影响已超过一年。它对许多人来说是毁灭性的，并在许多方面挑战了我们所有人。虽然疫苗接种的出现似乎减少了病例数量，但结束大流行的多重挑战仍然存在，包括变种的出现、疫苗犹豫、获得疫苗以及疫苗在免疫功能低下人群中的效力受损。因此，继续研究COVID-19的治疗方法仍然至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The Return of Tocilizumab for Patients with COVID-19 Pneumonia

The COVID-19 pandemic has now impacted the global population for over a year. It has been devastating for many and has challenged us all in many ways. While the advent of vaccinations looks to curtail the number of cases, multiple challenges to ending the pandemic remain, including the advent of variants, vaccine hesitancy, access to vaccines, and the impaired efficacy of vaccines in immunocompromised persons. Thus, it is still essential to continue investigating treatments for COVID-19.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of cellular immunology

自引率

0.00%

发文量